|Title:|| Monomeric insulin analog formulations|
|Abstract:||The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.|
|Inventor(s):|| De Felippis; Michael R. (Indianapolis, IN) |
|Assignee:|| Eli Lilly and Company (Indianapolis, IN) |
1. Insulin analog-protamine crystals consisting essentially of: human insulin wherein Pro at position B28 is substituted with Lys, Leu, Val or Ala, and Lys at position B29 is Lys or Pro,
des(B28-B30)-human insulin, or des(B27)-human insulin; protamine; zinc; and a phenolic derivative.
2. Crystals of claim 1, which is Lys.sup.B28 Pro.sup.B29 -human insulin, about 0.27 to about 0.32 mg protamine/100 IU of insulin analog, about 0.35 to about 0.9% zinc by weight, and a phenolic derivative.